Participation in clinical trials is an individual, and important, decision. There are many advantages to participating in a trial, including care from medical teams experienced with the disease and the opportunity to try a new medication long before it is approved by the Food and Drug Administration to treat an indicated condition.
If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time. For more resources about trial participation and informed consent, please see the resources available from the U.S. Department of Health and Human Services.
Please note: Trials that are recruiting patients with eosinophil-associated disease and a search engine that can help match you to an enrolling trial appear below. Neither the list nor search engine results are considered exhaustive. The clinical trials listed here were verified as open and enrolling at the time the post was made, and are monitored periodically to ensure that the trial is still accepting participants. If a trial is no longer accepting patients, APFED may not be notified. If you find registration has closed for a trial that is still listed on this page, please notify mail@apfed.org.
Trials of Interest:
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
Ages: 18 and older
Study Reference: NCT05634746
Study Type: Interventional
Learn more at clinicaltrials.gov
Visit the study website
Download the study flier
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (EvolvE)
Ages: 18 and older
Study Reference: NCT05774184
Study Type: Interventional
Learn More at clinicaltrials.gov
| The CROSSING study for adults and adolescents with EoE | |
 | The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age. To learn more about participating in the study you can visit the website https://eoetrialandyou.com/APFED or call 844-432-3890. |
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
Ages: 18-75 years old
Study Reference: NCT05084963
Study Type: Interventional
Learn More at clinicaltrials.gov
Learn More at the study website
A Study to Evaluate the efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Ages: 12-75 years old
Study Reference: NCT04753697 and CC-93538-EE-001
Study Type: Interventional
Location: Multiple locations in U.S.
Learn More
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
Ages: 3-65
Study Reference: NCT02523118
Study Type: Observational
Location: Multiple locations in U.S.
Learn more
Download the flyer
Phase 2 Study of Esophageal String Test in Eosinophilic Esophagitis
Ages: 7-65
Study Reference: NCT02008903
Study type: Observational
Location: Children’s Hospital Colorado (Aurora, CO); Lurie Children’s Hospital (Chicago, IL); Northwestern University (Chicago, IL)
Learn more
Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools
Ages: 5-80
Study Reference: NCT02453126
Study type: Observational
Location: Mayo Clinic, Rochester, MI
Learn more
Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis
Ages: 18-80
Study Reference: NCT02434705
Study type: Interventional
Location: Mayo Clinic, Rochester, MI
Learn more
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (ANTI-IL4RA) in Subjects with Eosinophilic Gastritis
Ages: 12-71
Study Type: Interventional
Location: Multiple locations in U.S.
Learn more
DEGAS Recruitment Brochure
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
Ages: 3-65
Study Reference:NCT02523118
Study Type: Observational
Location: Multiple locations in U.S.
Learn more
OMEGA Advertisement Flyer pdf
Download the flyer
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Ages: consent obtained for ages 11+
Study Reference: NCT00267501
Study type: Observational
Location: Cincinnati, OH
Learn more
Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
OCEAN study for adults with eosinophilic granulomatosis with polyangiitis (EGPA)
Ages: 18 and older
Study Reference: 217102
Study type: Interventional
Location: Multiple
Learn more
Study Brochure
Study Fact Sheet
Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes
Ages: 0-20
Study Reference: NCT02006134
Study type: Observational
Location: Multiple, including international
Learn more
Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Ages: any age
Study Reference: NCT00315380
Study type: Observational
Location: Multiple, including Canada
Learn more
Vasculitis Pregnancy Registry
Ages: 18-50 Female
Study Reference: NCT02593565
Study Type: Observational/Patient Registry
Location: Online Registry
Learn more
Hypereosinophilic Syndromes
Study in Pediatrics with Hypereosinophilic Syndrome (SPHERE)
Ages: 6 years - 17 years
Study Reference: 215360
Study Type: Interventional
Location: Multiple
Study Website
Brochure
Study Fact Sheet
Depemokimab Efficacy and Safety Study in Hypereosinophilic Syndrome (DESTINY)
Ages: 18 years and older
Study Reference: 217013
Study Type: Interventional
Location: Multiple
Study Website
Study Fact Sheet
Study Brochure
A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON)
Ages: 12 and older
Study Reference: NCT04191304
Study type: Interventional
Location: Multiple
Learn more
Related webpage (for sharing)
Physician fact sheet (adult patients)
Physician fact sheet (minor + adult patients)
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Ages: any age
Study Reference: NCT00091871
Study type: Observational
Location: Bethesda, MD
Learn more
Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients With Myeloproliferative and/or Steroid-Refractory Hypereosinophilic Syndrome
Ages: 2+
Study Reference: NCT00044304
Study type: Interventional
Location: Bethesda, MD
Learn more
Eosinophilic Fasciitis
Coordination of Rare Diseases at Sanford
Ages: not specified
Study Reference: NCT01793168
Study type: Observational
Location: Sioux Falls, SD
Learn more